Short answer
Zymeworks Inc. (ZYME) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $256M (up 828.7% year over year) with net income of $174M.
Q3 2026 key financials · XBRL
- Revenue
- $256M
- +828.7% YoY · +5487.4% QoQ
- Net income
- $174M
- +986.1% YoY · +485.8% QoQ
- Operating margin
- 69.2%
- EPS (diluted)
- $2.29
- +980.8% YoY · +469.4% QoQ
Source: XBRL data from the Zymeworks Inc. (ZYME) Q3 2026 10-Q on SEC EDGAR. USD.
Zymeworks Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $256.5M vs $27.6M, up $228.9M YoY, driven by $250.0M Jazz milestone
- Royalty and other revenue $4.9M vs $2.4M, while YUPELRI collaboration revenue contributed $1.5M
- R&D expense $36.1M vs $35.6M, SG&A $42.7M vs $14.1M, with no quarterly margin figures disclosed
- Cash $100.5M at September 30, operating cash flow nine-month outflow $101.7M vs $22.7M
- $14.0M Q3 share repurchases, $532.0M Theravance acquisition payment, $250.0M Jazz milestone received October 2026
- Outlook: cash plus Jazz milestone funding expected for at least twelve months, 2026 profitability anticipated but inconsistent quarterly profitability expected
Risk Factors
- New trade-compliance risk: BIOSECURE Act and DOJ Data Security Program could restrict Chinese suppliers and sensitive-data transfers
- Most material update: 10% global import surcharge and proposed 100% pharmaceutical tariff, threatening China-sourced clinical supplies
- Regulatory risk: FDA accelerated BTC approval for Ziihera remains contingent on confirmatory-trial benefit
- Operational risk: single YUPELRI API supplier, drug-product supplier and warehouse create concentrated supply exposure
- Financial risk: $100 million TRELEGY ELLIPTA milestone anticipated in Q1 2027, subject to conditions and unavailable development information
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Zymeworks Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.